<DOC>
	<DOCNO>NCT01248949</DOCNO>
	<brief_summary>To determine maximum tolerate dose optimal biological dose , safety profile MEDI3617 give single-agent combination chemotherapeutic agent subject advance solid malignancy resistant standard therapy .</brief_summary>
	<brief_title>A Study Evaluate Safety Antitumor Activity Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients confirm diagnosis advance solid tumor ( doseescalation phase ) another solid tumor type base antitumoral activity ( doseexpansion phase ) responsive standard therapy standard therapy exist Patients must 18 year age old Karnofsky Performance Status â‰¥ 70 Toxicities previous cancer therapy must recover CTCAE Grade = &lt; 2 Adequate organ marrow function Using adequate contraceptive measure , surgically sterile postmenopausal Concurrently enrol another clinical study , except noninterventiona observational study , follow period previous study Receipt investigational anticancer therapy within 30 day prior first dose MEDI3617 , case monoclonal antibody ( eg , bevacizumab ) , 42 day prior first dose MEDI3617 Current previous treatment angiopoietin inhibitor , inhibitor Tie1 Tie2 include , limited , AMG386 , CVX060 , XL880 , XL820 Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic hormonal therapy cancer treatment Use immunosuppressive medication systemic steroid within 7 day prior first dose MEDI3617 Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Known bleed diathesis Pulmonary hemorrhage gross hemoptysis within 6 month prior enrollment Therapeutic palliative radiation therapy within 2 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Advanced recurrent ovarian tumor</keyword>
	<keyword>MEDI3617</keyword>
	<keyword>Ang2</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Malignant glioma</keyword>
</DOC>